Perspective Therapeutics (FRA:AAJ0) ROCE %: -33.96% (As of Mar. 2026)


FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
31 GF Score
Price €2.56
! 1 Warning Sign
View Full Analysis

What is Perspective Therapeutics ROCE %?

Perspective Therapeutics FRA:AAJ0 +3.72% 31 ROCE % is -33.96% as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Perspective Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -33.96%.

Perspective Therapeutics  (FRA:AAJ0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Perspective Therapeutics ROCE % Related Terms

Perspective Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics ROCE % Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.02 -12.08 -54.69 -40.01 -34.72

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.21 -27.54 -35.90 -59.73 -33.96
FRA:AAJ0
31GF Score
Perspective Therapeutics Inc FRA:AAJ0
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics ROCE % Calculation

Perspective Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-88.86/( ( (325.751 - 17.41) + (227.994 - 24.492) )/ 2 )
=-88.86/( (308.341+203.502)/ 2 )
=-88.86/255.9215
=-34.72 %

Perspective Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-90.252/( ( (227.994 - 24.492) + (355.315 - 27.235) )/ 2 )
=-90.252/( ( 203.502 + 328.08 )/ 2 )
=-90.252/265.791
=-33.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -33.96% mean?
Perspective Therapeutics (FRA:AAJ0) has a ROCE % of -33.96% as of Mar. 2026.
Is Perspective Therapeutics' ROCE % too high?
Perspective Therapeutics' current ROCE % is -33.96%. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' ROCE % compare to LAB and KIDS?
Perspective Therapeutics' ROCE % of -33.96% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current ROCE % is -33.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current ROCE % of -33.96%. The current ROCE % is -33.96%. Perspective Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current ROCE % is -33.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for FRA:AAJ0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price